{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mouron S"],"funding":["NIMHD NIH HHS"],"pagination":["7529"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9729295"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Precision oncology research is challenging outside the contexts of oncogenic addiction and/or targeted therapies. We previously showed that phosphoproteomics is a powerful approach to reveal patient subsets of interest characterized by the activity of a few kinases where the underlying genomics is complex. Here, we conduct a phosphoproteomic screening of samples from HER2-negative female breast cancer receiving neoadjuvant paclitaxel (N = 130), aiming to find candidate biomarkers of paclitaxel sensitivity. Filtering 11 candidate biomarkers through 2 independent patient sets (N = 218) allowed the identification of a subgroup of patients characterized by high levels of CDK4 and filamin-A who had a 90% chance of achieving a pCR in response to paclitaxel. Mechanistically, CDK4 regulates filami"],"journal":["Nature communications"],"pubmed_title":["Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A."],"pmcid":["PMC9729295"],"funding_grant_id":["L60 MD003733"],"pubmed_authors":["Sabroso-Lasa S","Quintela-Fandino M","Sanchez-Bayona R","Fustero-Torre C","Manso L","Garcia-Saenz JA","Moreno A","Gomez-Lopez G","Munoz J","Murillo R","Gonzalez-Cortijo L","Malats N","Colomer R","Mouron S","Martinez-Janez N","Lluch A","Calvo I","Malumbres M","Bueno MJ","Caleiras E","Ximenez-Embun P","Gil-Gil M","Apala JV","Martinez M","Megias D","Cejalvo JM","Cortes J"],"additional_accession":[]},"is_claimable":false,"name":"Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.","description":"Precision oncology research is challenging outside the contexts of oncogenic addiction and/or targeted therapies. We previously showed that phosphoproteomics is a powerful approach to reveal patient subsets of interest characterized by the activity of a few kinases where the underlying genomics is complex. Here, we conduct a phosphoproteomic screening of samples from HER2-negative female breast cancer receiving neoadjuvant paclitaxel (N = 130), aiming to find candidate biomarkers of paclitaxel sensitivity. Filtering 11 candidate biomarkers through 2 independent patient sets (N = 218) allowed the identification of a subgroup of patients characterized by high levels of CDK4 and filamin-A who had a 90% chance of achieving a pCR in response to paclitaxel. Mechanistically, CDK4 regulates filami","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T00:40:16.299Z","creation":"2025-02-18T23:34:42.243Z"},"accession":"S-EPMC9729295","cross_references":{"pubmed":["36477027"],"doi":["10.1038/s41467-022-35065-z"]}}